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OBJECTIVE: To test impact of including (versus exclud-
ing) health states perceived to be worse than death on
utility measurement using standard gamble (SG) and vi-
sual analogue scale (VAS) methods. METHODS: Face-
to-face interviews were conducted in a convenience sam-
ple of women aged 22 to 50 years with no history of
breast cancer or cancer requiring chemotherapy (n 
119). Data were collected between March 2000 and June
2000 at a Midwestern University in the US. Subjects were
asked to rate their utility if faced with three hypothetical
breast cancer health states: cure, treatment and recur-
rence. Utility weights were estimated using SG top-down
titration and VAS methods scaled from zero (death) to
one (perfect health). Linear transformation was used to
allow for negative preference weights for health states
worse than death. RESULTS: Unpaired t-test analysis
showed statistically significant greater change in SG (n 
16) and VAS (n  17) utilities for respondents perceiving
cancer recurrence as worse than death than those perceiv-
ing death as least desirable health state (p  0.05). Mean
change in SG (VAS) utility allowing for health states
worse than death for breast cancer cure versus treatment,
treatment versus recurrence, and cure versus recurrence
were 0.066(0.226), 0.335(0.339), and 0.401(0.564), re-
spectively (n  119). Excluding negative utilities from
study resulted in statistically
significant lower mean changes in utility weights (SG n 
103, VAS n  102). CONCLUSION: Most studies typi-
cally measure health preferences excluding health states
perceived as worse than death. Similar to Patrick et al
(1994) results of this study indicate health preference
elicitation methods can be successfully adapted to acquire
negative utilities. Regardless of metric used, both SG and
VAS yield higher changes in weight estimates when nega-
tive utilities are permitted. Addressing negative utilities in
studies could significantly affect QALY estimates in eco-
nomic analyses.
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OBJECTIVES: This study aims to estimate the cost-effec-
tiveness (CE) of irinotecan5FU/FA versus 5FU/FA alone
in the first line treatment of advanced metastatic colorec-
tal cancer from the perspective of the UK National
Health Service. METHODS: A decision tree model was
designed in Excel to track patients through the course of
advanced colorectal disease based upon trial data from
first line management and estimating average survival
and associated resource use. A systematic review and
meta analysis were undertaken for first line treatment
with irinotecan and 5FU/FA and 5FU/FA alone to pro-
vide data on response rate, time to progression, survival
rates (median survival 67.5 weeks versus 55 weeks), drop
out from toxicities, and major adverse events. Medica-
tion costs were based on the British National Formulary
and allow for wastage. Resource utilization for routine
treatment and monitoring, adverse event management,
use of second line chemotherapy, palliative care and
other clinical parameters was elicited from a survey of
five UK oncologists experienced with the therapies.
Wherever possible, acquisition costs from published sources
were applied to the resources. RESULTS: The total costs
including drug, treatment administration, management of
toxicity and of disease progression amounted to £23,825
per patient treated with CPT-115FU/FA and £18,795
per patient treated with 5FU/FA alone. When the differ-
ence in cost is related to the clinical benefit of irinotecan,
the cost per life year gained was estimated as £20,948.
Sensitivity analysis showed that the analysis was robust
as the CE ratios did not widely vary. CONCLUSION: In
the treatment of advanced metastatic colorectal cancer in
the UK, irinotecan5FU/FA extends survival and the cost
remains within the limits currently accepted for new che-
motherapeutic agents.
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OBJECTIVES: Lung cancer is a leading cause of morbid-
ity and mortality. Chemotherapy is a main treatment op-
tion but its availability in the UK is limited and not con-
sistent across geographical regions. This study reports on
an economic evaluation of Gemzar/cisplatin (GC) relative
to: mitomycin/ifosfamide/cisplatin (MIC), etoposide/
cisplatin (PE) and itomycin/vinblastine/cisplatin (MVP).
These represent standard platinum-containing regimens
that are currently used in the UK. METHODS: The study
perspective is that of the UK-NHS. Data were derived
from comparative clinical trials (Crino et al 1999, Carde-
nal et al. 1997, Costa 2000). Costing is based on: chemo-
therapy, infusion, hospitalisations, visits to health care
professionals and concomitant medications. Resource
utilisation from the trials was combined with unit cost
data from various UK sources. Costs correspond to 2000.
Time horizon for the estimation of costs is one year;
hence discounting was unnecessary. Treatment effective-
ness is measured by overall survival and objective tumour
response. RESULTS: In the first setting the cost-per-
patient on GC was £5,101 and on MIC £4,481. Overall
tumour response rates were 39.6% and 27.6% respec-
tively. Thus, the incremental cost-per-tumour-response of
GC was £5,169. In the second setting, the cost on GC
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was £4,142 compared to £3,762 on PE. Overall tumour
response was 40.6% and 21.9% respectively and progres-
sion-free life years 0.575 and 0.358. Thus, the incremen-
tal cost-per-tumour-response of GC was £2,032 and the
incremental cost-per-progression-free-life-year £1,751. In
the final setting, the cost of GC was £5,084 and of MVP
£4,004. Overall tumour response was 54.0% and 36.7%
and one year survival 36% and 17% respectively. The in-
cremental cost-per-tumour-response of GC was £6,240
and the incremental cost-per-survivor-at-one-year was
£5,681. In extreme changes to underlying variables the
above ratios vary from dominance to a maximum of
£14,000. CONCLUSIONS: These results demonstrate
that Gemzar/cisplatin represents a relatively cost-effective
treatment for NSCLC with ratios comparable of below
those of therapies currently in use within the NHS.
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OBJECTIVES: To identify the association between com-
pliance and the direct costs of care for two different clini-
cal patient cohorts. METHODS: Using administrative
claims data from Medstat MarketScan (tm) we assessed
the association between prescription drug compliance
and direct costs of care for two patient groups: a cohort
of non-Medicare patients diagnosed as diabetics (N 
9960) and second cohort of non-Medicare patients diag-
nosed with congestive heart failure (CHF)(N  935).
Since patients who are more compliant tend to be older
and have a greater number of comorbidities, and our goal
was to isolate the association between compliance and
medical care costs, we statistically controlled for differ-
ences in potential confounding variables using OLS re-
gression. Covariates included age, gender, comorbidity
indices (Chronic Disease Score and Charlson-Deyo), and
ICD-9-based severity of illness indicators. Compliance
was defined by calculating % days supply over a period
of one year. Compliance was then converted to 7 ordinal
categories in the regression model in order to identify
dose-response associations or threshold/inflection points.
RESULTS: Among diabetics, those who did not use any
prescription medication showed the lowest total costs of
care. However, among those patients who needed pre-
scription medication to manage their illness, increased
prescription drug costs among the most compliant are
more than offset by decreases in medical care costs, for
an estimated return on investment (ROI) of more than
two-fold. A similar, but stronger, pattern was found
among patients with CHF where the estimated ROI was
three-fold or greater. CONCLUSIONS: For some medi-
cal conditions, the additional costs associated with in-
creased compliance may be offset by lower medical costs,
resulting in an ROI greater than one.
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OBJECTIVES: Health care decision-makers need more
head-to-head drug comparison trials. Industry rarely
sponsors such studies, preferring placebo comparators.
We present an example of using meta-analysis for an in-
direct comparison of 2 drugs, with the results subse-
quently validated in a direct comparison trial. METH-
ODS: The drugs for comparison were abciximab and
tirofiban, both GPIIb/IIIa inhibitors used in patients with
acute coronary syndromes undergoing percutaneous cor-
onary interventions (PCI). A class effect has been as-
sumed for these agents, although they differ in molecular
structure and duration of action. We identified all pla-
cebo-controlled trials of each drug in PCI patients, and
meta-analysed the odds ratios (OR) for death or MI
(D/MI) at 30 days for each set of studies. These ORs were
then compared using a general linear model. RESULTS:
For D/MI at 30 days, the results of the meta-analysis of
the 6 abciximab studies [OR  0.52 (0.43, 0.63)] ap-
peared superior to the results of the 3 tirofiban studies
[OR  0.73 (0.55, 0.96)], although the differences did
not reach significance. In the model, a non-significant (p 
0.10) abciximab advantage was observed. The ratio of
the ORs of tirofiban/placebo and abciximab/placebo
meta-analyses was 1.4, suggesting a higher risk of D/MI
at 30 days for tirofiban relative to abciximab. After com-
pletion of these analyses, the results of a randomized
comparison trial of tirofiban vs. abciximab in PCI pa-
tients were announced (for D/MI at 30days OR  1.26,
p  0.04). The results demonstrated an advantage for ab-
ciximab, in keeping with our meta-analysis result. The
magnitude of the efficacy difference was similar to that
we had predicted. CONCLUSIONS: This is the first time
an indirect comparison of drugs using meta-analytic tech-
niques has been validated with a contemporaneous RCT.
This method should be used to predict results of direct
comparisons of drugs anytime such a trial is contem-
plated.
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OBJECTIVES: The cost of remifentanil, a short-acting
opiate, is approximately 10 times higher than fentanyl, a
